<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nguyen HP</submitter><funding>Ministry of Education</funding><funding>Bộ Giáo dục và Ðào tạo</funding><funding>Ministry of Science and ICT, South Korea</funding><pagination>22108-22118</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364358</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(34)</volume><pubmed_abstract>Multiple myeloma is a deadly cancer that is a complex and multifactorial disease. In the present study, 12 belinostat derivatives (four resynthesized and eight new), HDAC inhibitors, were resynthesized &lt;i>via&lt;/i> either Knoevenagel condensation, or Wittig reaction, or Heck reaction. Then an evaluation of the antiproliferative activities against myeloma cells MOPC-315 was carried out. Amongst them, compound 7f was the most bioactive compound with an IC&lt;sub>50&lt;/sub> of 0.090 ± 0.016 μM, being 3.5-fold more potent than the reference belinostat (IC&lt;sub>50&lt;/sub> = 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent tha</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies.</pubmed_title><pmcid>PMC9364358</pmcid><funding_grant_id>2018R1A6A1A03025523</funding_grant_id><funding_grant_id>B2019-TCT-37 (TCT-05)</funding_grant_id><funding_grant_id>2020R1A2B5B02002377</funding_grant_id><funding_grant_id>2019M3E5D1A02069623</funding_grant_id><pubmed_authors>Nguyen CQ</pubmed_authors><pubmed_authors>Tuan NT</pubmed_authors><pubmed_authors>Van Ky N</pubmed_authors><pubmed_authors>Hoa TP</pubmed_authors><pubmed_authors>Nguyen HP</pubmed_authors><pubmed_authors>Le Dang Q</pubmed_authors><pubmed_authors>Hue BTB</pubmed_authors><pubmed_authors>Quoc Chau Thanh N</pubmed_authors><pubmed_authors>Nhu Thao H</pubmed_authors><pubmed_authors>Pham MQ</pubmed_authors><pubmed_authors>Duy Binh T</pubmed_authors><pubmed_authors>Tran Q</pubmed_authors><pubmed_authors>Yang SG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies.</name><description>Multiple myeloma is a deadly cancer that is a complex and multifactorial disease. In the present study, 12 belinostat derivatives (four resynthesized and eight new), HDAC inhibitors, were resynthesized &lt;i>via&lt;/i> either Knoevenagel condensation, or Wittig reaction, or Heck reaction. Then an evaluation of the antiproliferative activities against myeloma cells MOPC-315 was carried out. Amongst them, compound 7f was the most bioactive compound with an IC&lt;sub>50&lt;/sub> of 0.090 ± 0.016 μM, being 3.5-fold more potent than the reference belinostat (IC&lt;sub>50&lt;/sub> = 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent tha</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2026-05-09T19:35:05.067Z</modification><creation>2025-04-21T14:47:28.683Z</creation></dates><accession>S-EPMC9364358</accession><cross_references><pubmed>36043105</pubmed><doi>10.1039/d2ra01969h</doi></cross_references></HashMap>